Sarah is 51. She is a nurse practitioner. She knows what good medicine looks like. She has been on bioidentical hormone replacement therapy for 10 months. Her labs are adequate. Her providers have looked at everything conventional training would tell them to look at, and she is still not responding. She is becoming more and more frustrated. She is experiencing fatigue that peaks every afternoon. Her sleep breaks around two in the morning and will not come back.
Weight gain has become an issue. Eleven pounds she cannot explain. Brain fog that is causing her to lose words mid-sentence and is affecting her patient care. Two providers. Eighteen months. No real answers.
In this episode I am going to show you exactly what was missed and why. Not a dosing problem. Not a compliance problem. A clinical reasoning problem. And by the time we finish I want you to see something you cannot unsee about how these patients actually need to be worked up.
I am Dr. Sheri Erwin, founder of BridgeWell Integrative Education. Welcome to BridgeWell Grand Rounds.
Let's take a closer look at Sarah. She is a 51-year-old on BHRT and she is still not feeling better. The fatigue is affecting her afternoons. The sleep disturbances have her falling asleep but waking between two and three in the morning and unable to go back to sleep. The brain fog is affecting her patient encounters. Eleven pounds of unexpected weight gain despite no significant dietary changes is becoming increasingly frustrating. And her mood she describes as flat. Not depressed. Just flat.
She has been to two providers. Both looked at her hormones. Both said her estradiol and progesterone were adequate. One slightly adjusted her dose but nothing produced a significant change. She is eighteen months into this and she still has no real answers.
So what do most providers do next? Here is where conventional training tends to go at this point. The labs look adequate so the assumption becomes that the treatment is working and the symptoms are something else. Maybe she needs a mood evaluation. Maybe she needs a sleep study. Maybe the fatigue is depression presenting atypically.
I want to be direct about this. When a patient on adequate hormone therapy is still symptomatic, the answer is almost never in the hormone levels. The answer is in the environment those hormones are operating in. Hormones do not work in isolation. They work in a signaling environment. And when that environment is dysregulated, even adequate hormone levels cannot do their job.
That is what systems-based clinical reasoning asks first. What is the signaling environment doing? And the two most important systems to assess in Sarah's case are the HPA axis and the gut.
Why cortisol comes first. The first thing I want to know about Sarah is not what her estrogen level is. I want to know what her cortisol is doing. I know that sounds counterintuitive for a BHRT patient, but here is the physiology. Chronically elevated cortisol competes with progesterone at the glucocorticoid receptor. They share the same receptor site. Cortisol wins. So even with adequate progesterone present, a patient with HPA dysregulation has progesterone that cannot fully do its job.
And when cortisol is low or flat, which is where we often end up after prolonged HPA stress, the downstream effects on energy, sleep architecture, and mood are exactly what Sarah is describing. Fatigue that peaks in the afternoon. Sleep disturbances. A flat mood. These are HPA signals before they are hormonal signals.
Sarah's HPA markers. Here is what her cortisol story looks like. Her morning serum cortisol is 12.4 micrograms per deciliter. Within standard range, but at the low-normal end of the functional range. I want to see morning cortisol between 15 and 25.
Four-point salivary cortisol showing a flat diurnal curve. No clear morning rise. No healthy afternoon decline. The pattern is blunted across the day.
DHEA-S at 68 micrograms per deciliter. Low for her age. That tells me adrenal reserve is depleted.
This is an HPA axis that has been under chronic stress load. Not dramatically. Her serum cortisol is not crashing. But the pattern tells a story of sustained demand on a system that no longer has reserve.
The flat diurnal curve is particularly important. Healthy cortisol follows a predictable arc. High in the morning to support energy and cognition. A gradual decline through the day. A low nadir at night to allow restorative sleep. When that curve is flat, the entire system is operating without its normal rhythm. Morning energy never comes. Afternoon fatigue becomes severe. The low nadir at night disappears and sleep architecture breaks down. That is Sarah's symptom pattern exactly.
What this means clinically. HPA axis dysregulation is not adrenal fatigue in the colloquial sense. It is a measurable disruption in the cortisol diurnal rhythm that has downstream consequences for every hormone in the body. For Sarah it explains why her progesterone is not working at the receptor level, why her sleep is fragmented, why her energy is depleted, and why adjusting her estradiol dose has not moved the needle.
You cannot fix a hormone environment problem by adjusting the hormone. You have to fix the environment first.
We will come back to interventions in Episode 3. But for now I want you to hold this question. If the HPA axis is generating this much downstream disruption, what else is being affected?
The answer is the gut. And that is where we are going next.
The gut's role in hormone metabolism. Most clinicians think about the gut in terms of digestive symptoms. Bloating. Irregular bowel habits. Reflux. But the gut's role in hormonal health goes far beyond digestion.
The estrobolome is the collection of gut bacteria responsible for metabolizing estrogen. Specifically, certain bacteria produce an enzyme called beta-glucuronidase that deconjugates estrogen in the gut, allowing it to be reabsorbed into circulation. When the estrobolome is disrupted, this process goes wrong in one of two directions.
Too much beta-glucuronidase activity and estrogen is deconjugated and reabsorbed at higher rates. Estrogen recirculates. Estrogen burden increases. The patient becomes relatively estrogen dominant even on a standard BHRT dose.
Too little beta-glucuronidase activity and estrogen is excreted rather than recirculated. Estrogen levels drop. The patient appears not to be absorbing her BHRT even when she is.
Either direction creates a hormonal picture that looks like a dosing problem but is actually a gut problem.
Sarah's gut markers. Sarah's gut picture is telling. She has not had significant GI symptoms. No bloating she would describe as significant. Bowel habits are slightly irregular but she has had that for years. But her labs tell a different story.
Her serum zonulin is elevated at 42 nanograms per milliliter. That indicates disrupted intestinal tight junction integrity. The gut barrier is permeable.
Her LPS antibodies are positive. That tells me bacterial endotoxins are crossing the gut barrier and entering systemic circulation. This drives a low-grade systemic inflammatory response that conventional labs will miss entirely.
Her high-sensitivity CRP is 2.8 milligrams per liter. Just inside the standard reference range. But the functional target I want to see is below 1.0. At 2.8 there is meaningful systemic inflammation present.
And her organic acids test shows elevated arabinose, which suggests yeast overgrowth in the gut, and elevated citramalic acid, which suggests bacterial overgrowth contributing to the dysbiosis picture.
Connecting the gut to the hormonal picture. Here is what this gut picture is doing to Sarah's BHRT. The intestinal permeability is generating a low-grade systemic inflammatory response. That inflammation directly impairs hormone receptor sensitivity. The cells that should be responding to estrogen and progesterone are downregulating their receptors in the context of ongoing inflammation.
The dysbiosis is disrupting her estrobolome. The specific bacterial balance needed to properly metabolize and recirculate estrogen is compromised. So even with adequate serum estradiol, the effective tissue exposure may be significantly different from what the lab value suggests.
And the cortisol burden from the HPA axis dysregulation we discussed is directly feeding the gut dysfunction. Chronic cortisol elevation increases intestinal permeability. The HPA axis and the gut are in a bidirectional loop, each making the other worse.
This is what systems-based reasoning reveals that single-system thinking misses. Sarah does not have a hormonal problem. She has a hormonal environment problem with two major drivers: HPA axis dysregulation and gut-estrobolome dysfunction. And they are connected.
In this episode we established two things clearly. Sarah's HPA axis is dysregulated in a way that is directly impairing her progesterone receptor function and disrupting her sleep architecture. And her gut barrier is permeable, her estrobolome is compromised, and the resulting systemic inflammation is impairing her hormone receptor sensitivity throughout her body.
In Episode 2 we are going to look at two more upstream questions. What is the metabolic picture doing, specifically her insulin signaling, and what does her neuroinflammation workup show. By the time we reach Episode 3 we will have a complete upstream clinical picture and I will walk you through exactly how you sequence the interventions so you are addressing root causes in the right order rather than chasing symptoms.
If this clinical reasoning resonates with you and you want to go deeper, the BridgeWell Transformation Pathway is where nurse practitioners build this kind of thinking into how they practice every day. The link is in the episode description.
Thank you for being here. I look forward to having you in Episode 2. This is BridgeWell Grand Rounds and I am Dr. Sheri Erwin.
